Verastem Inc (VSTM) Stock Price, Quote & News

Company Profile

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 292 4200

Website: www.verastem.com

Address:

117 Kendrick Street, Suite 500, Needham, United States

Universaal Oct. 4 at 4:21 PM

$VSTM I like these technicals

0 · Reply

LiquidThetaLEAPS Oct. 4 at 9:37 AM

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $VSTM Current Share Price: $8.70 Contracts: $VSTM January 15, 2027 $10 Calls Scale in: $3.78- $4.62 Scale out: $5.88-$7.56 Can Easily Capture: 60% ROI Blended DTE: 469 Days | Join Elites here: https://liquidtheta.com/options

0 · Reply

Universaal Oct. 3 at 9:20 PM

$VSTM closing above $9 seems hard rejected 8 times.. this is undoubtedly going to see 7.50$

2 · Reply

TXDave Oct. 3 at 9:09 PM

$VSTM Short interest is something to consider. It can add unwarranted volitility both ways. While I hate games involved, they are a fact of life so my take is to ignore that stock price movement provide meaningful information, they may not.

2 · Reply

SagehenNed Oct. 3 at 7:59 PM

$VSTM Horrible close as always. Never ends on a good note.

1 · Reply

SagehenNed Oct. 3 at 6:40 PM

$VSTM $9 seems like a barrier.

0 · Reply

Robertbuote Oct. 3 at 6:10 PM

$VSTM Oct 20.

0 · Reply

outlawinvestor1 Oct. 3 at 4:38 PM

$ERAS #KRAS landscape. SA doesn't update mc/ev in real-time - ERAS mc is now ~$720 million, cash is ~$350 million. @Night_Owl_Biotech $RVMD $VSTM $ELTX $ARVN

0 · Reply

CrozrX Oct. 3 at 3:59 PM

$VSTM EMA 🇪🇺

0 · Reply

incipit Oct. 3 at 3:43 PM

$VSTM Do we know when the NCCN meets this month?

1 · Reply

Verastem Oncology to Present at Upcoming Investor Conferences

Aug 13, 2025, 4:29 PM EDT - 7 weeks ago

Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics' Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer

Aug 8, 2025, 8:55 PM EDT - 2 months ago

Verastem, Inc. (VSTM) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 2 months ago

Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates

Jul 29, 2025, 7:30 AM EDT - 2 months ago

Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 24, 2025, 7:30 AM EDT - 2 months ago

Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer

Jul 16, 2025, 8:22 AM EDT - 2 months ago

Verastem: The Market Is Ignoring The Progress

Jul 11, 2025, 4:12 PM EDT - 3 months ago

Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology

Jul 8, 2025, 7:30 AM EDT - 3 months ago

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 30, 2025, 4:02 PM EDT - 3 months ago

Verastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade Serious Ovarian Cancer

Jun 26, 2025, 11:16 AM EDT - 3 months ago

Verastem: Approval Secured, Moving On To PDAC And KRAS G12D-Related Cancers

Jun 24, 2025, 4:02 PM EDT - 3 months ago

Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors

Jun 2, 2025, 9:40 AM EDT - 4 months ago

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor

May 28, 2025, 7:30 AM EDT - 4 months ago

Verastem Oncology to Present at the Jefferies Global Healthcare Conference

May 22, 2025, 5:01 PM EDT - 4 months ago

Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma

May 20, 2025, 8:30 AM EDT - 4 months ago

Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment

TEM

May 13, 2025, 4:34 PM EDT - 5 months ago

Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates

May 8, 2025, 1:17 PM EDT - 5 months ago

FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer

May 8, 2025, 12:23 PM EDT - 5 months ago

U.S. FDA approves Verastem's cancer therapy

Apr 25, 2025, 9:00 AM EDT - 5 months ago

Verastem Oncology Announces $75 million Private Placement

Apr 23, 2025, 4:05 PM EDT - 5 months ago

Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors

Apr 10, 2025, 2:35 PM EDT - 6 months ago

Verastem: RAMP-203 Study Could Be Next Big Win For Avutometinib Combination

Mar 25, 2025, 4:35 PM EDT - 6 months ago

Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025

Mar 20, 2025, 4:01 PM EDT - 7 months ago

Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

Feb 20, 2025, 4:05 PM EST - 8 months ago

Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer

Jan 29, 2025, 7:30 AM EST - 8 months ago

Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference

Jan 23, 2025, 7:30 AM EST - 9 months ago

Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers

Jan 15, 2025, 7:30 AM EST - 9 months ago

Verastem Oncology Names Matthew E. Ros as Chief Operating Officer

Jan 14, 2025, 7:30 AM EST - 9 months ago

Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China

Jan 13, 2025, 7:30 AM EST - 9 months ago

Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025

Jan 3, 2025, 11:56 AM EST - 9 months ago

Verastem: Planning The PDUFA Run-Up

Jan 2, 2025, 11:39 AM EST - 9 months ago

Verastem: BLA Acceptance Puts Key Goals In Sight

Dec 31, 2024, 10:59 AM EST - 9 months ago

Why Is Cancer-Focused Verastem Oncology Stock Trading Higher On Tuesday?

Dec 30, 2024, 4:30 PM EST - 9 months ago

Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Dec 18, 2024, 7:30 AM EST - 10 months ago

Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

Nov 27, 2024, 1:28 PM EST - 11 months ago

Verastem: Preparing For Upcoming Catalysts

Nov 26, 2024, 7:00 AM EST - 11 months ago

Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference

Nov 6, 2024, 4:05 PM EST - 11 months ago

Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates

Oct 31, 2024, 4:01 PM EDT - 1 year ago

Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Oct 31, 2024, 7:30 AM EDT - 1 year ago

Verastem Oncology to Participate in Upcoming Investor Conferences

Oct 17, 2024, 1:00 AM EDT - 1 year ago

Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting

Oct 9, 2024, 6:00 AM EDT - 1 year ago

Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting

Sep 10, 2024, 4:05 PM EDT - 1 year ago

Verastem Oncology to Present at the 2024 Cantor Global Healthcare Conference

Sep 10, 2024, 7:30 AM EDT - 1 year ago

Verastem Oncology to Present Mature RAMP 201 Data in Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society 2024 Annual Meeting

Sep 5, 2024, 11:21 PM EDT - 1 year ago

Verastem's Path To FDA Approval: High-Risk, High-Reward Oncology Opportunity

Sep 3, 2024, 7:30 AM EDT - 1 year ago

Verastem Oncology and STAAR Ovarian Cancer Foundation Establish the Inaugural Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day on September 9, 2024

Aug 8, 2024, 4:05 PM EDT - 1 year ago

Verastem Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Updates

Jul 29, 2024, 4:01 PM EDT - 1 year ago

Verastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer

Jul 23, 2024, 11:20 PM EDT - 1 year ago

Verastem Oncology Announces Pricing of $55.0 Million Public Offering of Common Stock, Warrants and Pre-Funded Warrants

Jul 23, 2024, 4:05 PM EDT - 1 year ago

Verastem Oncology Announces Proposed Public Offering of Common Stock, Warrants and Pre-Funded Warrants

Universaal Oct. 4 at 4:21 PM

$VSTM I like these technicals

0 · Reply

LiquidThetaLEAPS Oct. 4 at 9:37 AM

0 · Reply

Universaal Oct. 3 at 9:20 PM

$VSTM closing above $9 seems hard rejected 8 times.. this is undoubtedly going to see 7.50$

2 · Reply

TXDave Oct. 3 at 9:09 PM

2 · Reply

SagehenNed Oct. 3 at 7:59 PM

$VSTM Horrible close as always. Never ends on a good note.

1 · Reply

SagehenNed Oct. 3 at 6:40 PM

$VSTM $9 seems like a barrier.

0 · Reply

Robertbuote Oct. 3 at 6:10 PM

$VSTM Oct 20.

0 · Reply

outlawinvestor1 Oct. 3 at 4:38 PM

$ERAS #KRAS landscape. SA doesn't update mc/ev in real-time - ERAS mc is now ~$720 million, cash is ~$350 million. @Night_Owl_Biotech $RVMD $VSTM $ELTX $ARVN

0 · Reply

CrozrX Oct. 3 at 3:59 PM

$VSTM EMA 🇪🇺

0 · Reply

incipit Oct. 3 at 3:43 PM

$VSTM Do we know when the NCCN meets this month?

1 · Reply

AUgold Oct. 3 at 2:37 PM

$VSTM I'm ready for $VSTM to drop a positive news bomb.

0 · Reply

ChesterKaita Oct. 3 at 2:04 PM

$VSTM Lets gooooo!

1 · Reply

Stoltz13 Oct. 3 at 1:02 PM

$VSTM anyone else see how we picked up the upward line from August 12-15 again? I think we keep moving that way...

1 · Reply

boston_drew Oct. 3 at 1:00 PM

$VSTM i talked to the desk, it should be a good day like CRSP yesterday have fun

1 · Reply

CrozrX Oct. 3 at 12:52 AM

$VSTM 10 arms, 330 patients now for VS-7375 study!! Moving quick!!

0 · Reply

Marketismanipulated2 Oct. 2 at 7:46 PM

$VSTM SURELY the thieves won't tank it AGAIN into the close..........will they? Rhetorical question of course!

1 · Reply

Bumbleclod Oct. 2 at 6:09 PM

$VSTM little C&H on the 6 month, maybe.......

1 · Reply

Universaal Oct. 2 at 2:56 PM

$VSTM sell and buy $SRPT thank me later

2 · Reply

OneSmartBull Oct. 2 at 2:42 PM

$VSTM PT 15

1 · Reply

LiquidThetaLEAPS Oct. 2 at 7:25 AM

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $VSTM Current Share Price: $8.80 Contracts: $VSTM January 15, 2027 $10 Calls Scale in: $3.63- $4.44 Scale out: $5.65-$7.27 Can Easily Capture: 60% ROI Blended DTE: 471 Days | Join Elites here: https://liquidtheta.com/options

0 · Reply

Alt_Fuel Oct. 2 at 6:40 AM

$VSTM VIDEO - Verastem's CEO Dan Paterson discusses the launch of the Avmapki Fakzynja Co-Pack for KRAS-mutated recurrent low-grade serous ovarian cancer, and other pipeline projects - September 8, 2025 https://www.biotechtv.com/post/verastem-oncology-september-8-2025 He discusses the launch of this combination, which was an accelerated approval, and arrived a couple of months sooner than the scheduled FDA decision date. Plus, why the confirmatory study is important, and pipeline progress on the G12D space. $RVMD

1 · Reply

AUgold Oct. 1 at 7:44 PM

$VSTM Sure looks like someone has a thumb on Both sides of the scale ⚖️

0 · Reply

Market Cap	535.44M
Revenue (ttm)	10.00M
Net Income (ttm)	-130.64M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,306.40%
Debt to Equity Ratio	2.06

Volume	1,536,500
Avg Vol	2,568,006
Day's Range	N/A - N/A
Shares Out	61.55M
Stochastic %K	32%
Beta	0.89
Analysts	Strong Sell
Price Target	$15.50